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Purpose of the study
The aim of this retrospective analysis was to review treat-
ment decisions and outcomes in HIV positive patients
with acute hepatitis C in a routine clinical setting. Out-
breaks of acute HCV infection have been described in
several cities recently. The epidemic affects mainly MSM
who are coinfected with HIV and is supposedly linked to
certain sexual risk practices. Here, we compared our
findings with current knowledge and recommendations.
Methods
HIV-positive patients with the diagnosis of acute HCV
infection were included in the retrospective analysis. The
patients came from outpatient infectious disease centers in
northern German cities. We looked at markers of HIV
and HCV infection and compared patients who received
treatment and those who did not. Treated patients were
followed up to 72 weeks.
Summary of results
Three hundred nineteen HIV-positive patients with acute
hepatitis C between 2001 and 2008 and were included in
the analysis. All patients were male, 315 (99%) patients
were of Caucasian origin, 296 (93%) declared homosexual
contacts as a risk factor for HCV infection, intravenous
drug use was declared in 3 (1%) cases. Median age at
HCV diagnosis was 40 years (range 20-69 years). Median
HCV viral load was 1.2 x 106 IU/mL. The HCV genotype
distribution was as follows: 222 patients (70%) had geno-
type 1, 7 (2%) genotype 2, 26 (8%) genotype 3, 59 (18%)
genotype 4. The median time of HIV infection was 5.5
years (range 0 to 22.4 years). Median HIV viral load was
110 copies/mL (range 25 to 10x10
6 copies/mL). The
median CD 4 count was 461 cells/mm
3 (range 55-1331
cells/mm
3). Two hundred and forty-six patients (77%)
received anti-HCV treatment, and 175 (55%) had com-
pleted therapy by the time of the analysis. Median treat-
ment duration was 33 weeks (IQR 24.1-49.9). 93 of the
175 treated patients (53%) reached a sustained virological
response (SVR). Treatment duration was significantly
higher in the SVR group (40.6 weeks vs 26.6 weeks,
p<0.0001). Seventy-three patients (23%) did not receive
anti-HCV treatment. In 19 of the untreated patients
(26%) the hepatitis C virus was cleared spontaneously.
Conclusions
Our findings indicate that acute hepatitis C in HIV
infected patients affects mainly MSM who acquire HCV
sexually. Patients had a short duration of HIV infection
and a stable immunological situation. In this real-life set-
ting from urban regions in northern Germany, treatment
rates appear to be high and effective.
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